QTEX · QTREX Quantum Ltd. · Insider Trading

The shares were purchased in the open market.

The shares were purchased in the open market. The purchase was made as part of the management share purchase plan announced by the Company on June 22, 2026.

The shares are held by Noonify Ltd., a company wholly owned by the Reporting Person. The Reporting Person may be deemed to be the beneficial owner of such shares.

The shares were purchased in the open market. The purchase was made as part of the management share purchase plan announced by the Company on June 22, 2026.

The shares were purchased in the open market. The purchase was made as part of the management share purchase plan announced by the Company on June 22, 2026.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on September 28, 2026 at prices ranging from $0.6897 to $0.7200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

This Form 4 Amendment is being filed solely to correct the amount of securities beneficially owned following reported transaction from 2,477,239 to 3,477,239.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on July 1, 2027, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on October 1, 2026, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on July 1, 2027, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on July 1, 2027, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold. The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold.

The options were granted with an exercise price of NIS 0.37.

The options were granted on November 1, 2020 and are fully vested as of June 1, 2022.

The options were granted with an exercise price of AUD 0.37.

The options were granted on February 15, 2020 and became fully vested as of June 2, 2019.

Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold. The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The options were granted on February 21, 2021 and became fully vested as of February 23, 2024.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.